JS 201
Alternative Names: JS-201Latest Information Update: 28 Jul 2024
At a glance
- Originator Shanghai Junshi Biosciences
- Developer Hunan Province Tumor Hospital; Shanghai Junshi Biosciences
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Programmed cell death 1 receptor antagonists; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in China (Parenteral, Injection)
- 30 Jun 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in China (Parenteral) (NCT04956926)
- 01 Jun 2021 Phase-II clinical trials in Small cell lung cancer (Second-line therapy or greater, Combination therapy) in China (IV) (NCT04951947)